ENvue Medical Inc. (FEED) just got a nice vote of confidence from a health system that knows its technology well. On Tuesday, the company announced that an integrated nonprofit health system running 12 hospitals across Virginia and North Carolina has renewed its contract for another three years, pushing the relationship out to 2028.
This isn't just a routine renewal. ENvue said the health system has adopted its ENvue Navigation Platform as the standardized protocol for bedside enteral feeding tube placement across all its hospitals. That means the platform is now baked into everyday clinical workflows, not just sitting on a shelf as an option someone might use occasionally.
"This renewal is a qualitatively different kind of milestone for ENvue," said Doron Besser, CEO of ENvue Medical. He sees the systemwide adoption as real-world validation of the platform's clinical performance.
The ENvue Navigation Platform is designed to help clinicians place feeding tubes at the bedside with real-time guidance, which can reduce complications and the need for X-ray confirmation. Getting a large health system to standardize on that technology is a big deal for a commercial-stage medical device company.
ENvue's strategy is to convert existing contracted access agreements into active clinical adoption while building longer-term relationships with hospitals. This renewal shows that approach is working within a large health network and supports the company's broader commercialization push.
This isn't the only good news ENvue has had recently. In March, the company announced a significant purchase of its platform and feeding tubes by a teaching hospital and Level I Trauma Center in the Detroit area. That partnership expanded ENvue's presence to 39 hospitals across the U.S.
And in January, ENvue inked a distribution deal with U-Deliver to sell its over-the-counter reusable ENFit Syringes through non-acute care channels nationwide. Those syringes are designed for both feeding and medication delivery.
Investors seemed to like the renewal news. ENvue shares were up 6.56% at $1.30 during premarket trading on Tuesday. But it's been a rough ride lately — the stock has declined about 23.3% over the past month, compared to a 9.1% rise in the S&P 500, and is down roughly 49% year-to-date versus the index's 7.8% gain.
Still, locking in a multi-year renewal with a 12-hospital system is the kind of tangible progress that could help turn sentiment around. For a company trying to prove its technology has staying power, having a health system commit to using it as the standard for the next three years is a pretty strong signal.
